Figure 1 (Figure1)
This text provides information on the proportion of subjects without events related to coronary heart disease death or nonfatal myocardial infarction. It includes survival distributions for both the placebo and pravastatin groups over a period of 5 years since randomization. The logrank statistic yielded a p-value of 0.0001, suggesting a significant difference between the two groups in terms of the events analyzed.*